Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHFOIX)

• Drug Name: OxycoDex Drug Info
• Synonyms: Oxycodone/dextromethorphan

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Discontinued in Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMHFOIX

Molecule-Related Drug Atlas

Drug(s) Targeting Opioid receptor (OPR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methadone	DMTW6IU	Advanced cancer	2A00-2F9Z	Approved	[4]
Ketobemidone	DMM3L6Z	Pain	MG30-MG3Z	Approved	[5]
Oxymorphone	DM65AGJ	Pain	MG30-MG3Z	Approved	[6]
Dextropropoxyphene	DM23HCX	Pain	MG30-MG3Z	Approved	[7]
Sufentanil	DMU7YEL	Analgesia	MB40.8	Approved	[8]
Naltrexone	DMUL45H	Alcohol dependence	6C40.2	Approved	[9]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[10]
Pentazocine	DM1XBHS	Pain	MG30-MG3Z	Approved	[11]
Nalmefene	DM4YWCZ	Opioid dependence	6C43.2Z	Approved	[12]
Tilidine	DMJW0VS	Pain	MG30-MG3Z	Approved	[13]

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[14]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[15]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[16]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[17]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[18]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[19]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[20]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[16]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[16]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[16]

Drug(s) Targeting Opioid receptor sigma 1 (OPRS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dextromethorphan	DMUDJZM	Allergic rhinitis	CA08.0	Approved	[21]
Dextromethorphan Polistirex	DMEHCY5	Dry cough	MD12	Approved	[16]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[22]
AVP-786	DMV1SOR	Alzheimer disease	8A20	Phase 3	[3]
ADX N05	DMLBYRA	Mood disorder	6A60-6E23	Phase 3	[23]
Igmesine	DMH97XA	Major depressive disorder	6A70.3	Phase 2	[24]
OPC-14523	DMB1WF3	Bulimia nervosa	6B81	Phase 2	[25]
ANAVEX 2-73	DM67OU4	Alzheimer disease	8A20	Phase 1	[26]
SSR-125047	DMSUFW6	Schizophrenia	6A20	Phase 1	[27]
SA-5845	DM6XZRL	Central nervous system disease	8A04-8D87	Phase 1	[28]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor (OPR)	TTN4QDT	NOUNIPROTAC	Modulator	[2]
Opioid receptor sigma 1 (OPRS1)	TT5TPI6	SGMR1_HUMAN	Modulator	[3]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017613)
• [2] Differential activation of the -opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model. Br J Pharmacol. 2013 Jan;168(2):375-88.
• [3] Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
• [4] Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
• [5] The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
• [7] Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
• [8] mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
• [9] An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
• [10] Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
• [11] Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
• [12] Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
• [13] Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
• [14] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [15] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [17] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [18] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [19] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [20] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [21] Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [23] Clinical pipeline report, company report or official report of SK BioPhamaceuticals.
• [24] Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19.
• [25] Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
• [26] 2011 Pipeline of Anavex.
• [27] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [28] Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45.